Intermediate Dose Prophylaxis in Adults with Haemophilia: A Clinical Audit from a Resource Limited Setting

  • Remya Sudevan
  • Aswathy Ashok Beenakumari
  • Rema Ganapathy
  • Manoj Unni
  • Geeta Vidyadharan
  • Neeraj SidharthanEmail author
Short Communication


To address the scarcity of real world data on adult prophylaxis from developing world, a short term intermediate dose prophylaxis in adult haemophilia A patients was initiated. A total of eight patients aged > 18 years with moderate/severe haemophilia A were given an average dose of 23 IU/kg recombinant factor VIII (rFVIII) concentrate twice weekly for 2 months. A clinical audit was done on completion of four months. The mean age of the participants was 31.63 (± 6.98) years. The mean bleed rate during two months of episodic versus prophylactic regimen was 5.13 versus 0.63 (p = 0.01) and that of work days lost, hospital visits for hemophilia care were 30.63 (± 24.69) versus zero days, 20.63 (± 16.19) versus zero days respectively. The mean of factor VIII consumed during prophylaxis was 13,500 IU/month (i.e., 23 IU/kg/dose).The median time gap between prophylactic infusion to trough level was 67.50 h (60–74 h) and the median trough level observed was 2.50% (range 1–5%). The results of our clinical audit show that Intermediate dose prophylaxis with rFVIII concentrates in young adult patients with moderate/severe haemophilia A appears to be effective in reducing the frequency of bleeds.


Hemophilia Intermediate dose Prophylaxis Adults 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Tagliaferri A et al (2008) Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfus 6(2):s17–s20PubMedPubMedCentralGoogle Scholar
  2. 2.
    Fischer K (2012) Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus 10(2):169–173PubMedPubMedCentralGoogle Scholar
  3. 3.
    Makris M (2012) Prophylaxis in haemophilia should be life-long. Blood Transfus 10(2):165–168PubMedPubMedCentralGoogle Scholar
  4. 4.
    Verma SP, Dutta TK, Mahadevan S, Nalini P, Basu D, Biswal N, Ramesh A, Charles D, Vinod KV, Harichandra Kumar KT (2016) A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia—a success story from a resource limited country. Haemophilia 22(3):342–348CrossRefPubMedGoogle Scholar
  5. 5.
    Sidharthan N, Sudevan R, Narayana Pillai V, Mathew S, Raj M, Viswam D, Joseph C, Sudhakar A (2017) Low-dose prophylaxis for children with haemophilia in a resource-limited setting in south India—a clinical audit report. Haemophilia 23(4):e382–e384CrossRefPubMedGoogle Scholar
  6. 6.
    Miners AH et al (1998) Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand’s disease. J Intern Med 244(6):515–522CrossRefPubMedGoogle Scholar
  7. 7.
    Nugent D et al (2018) Value of prophylaxis v/s on-deman d treatment: application of a value framework in hemophilia. Haemophilia 24(5):755–765CrossRefPubMedGoogle Scholar
  8. 8.
    Richards M et al (2007) Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 13(5):473–479CrossRefPubMedGoogle Scholar
  9. 9.
    Tagliaferri A et al (2008) Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 14(5):945–951CrossRefPubMedGoogle Scholar
  10. 10.
    Tiede A et al (2016) Prophylaxis vs. on-demand treatment with Nuwiq (Human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia 22(3):374–380CrossRefPubMedGoogle Scholar
  11. 11.
    Petrini P (2007) Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 13(2):16–22CrossRefPubMedGoogle Scholar
  12. 12.
    Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P et al (2010) ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 8(9):2063–2065CrossRefPubMedGoogle Scholar
  13. 13.
    Collins P et al (2010) Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 8(1):83–89CrossRefPubMedGoogle Scholar
  14. 14.
    Franchini M, Mannucci PM (2012) Prophylaxis for adults with haemophilia: towards a personalised approach? Blood Transfus 10(2):123–124PubMedPubMedCentralGoogle Scholar
  15. 15.
    Huang S, Li Z, Liu Y, Qin F, Feng X, Li Q, Zhou X, Sun J (2015) Comparison of short-term tertiary prophylaxis at low-dose and intermediate-dose for adults with severe hemophilia a in China. Blood 126:4681 CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  1. 1.Department of Health Sciences ResearchAmrita Institute of Medical Sciences, Amrita Vishwa VidyapeethamKochiIndia
  2. 2.Department of Hemato-OncologyAmrita Institute of Medical Sciences, Amrita Vishwa VidyapeethamKochiIndia
  3. 3.Department of HematopathologyAmrita Institute of Medical Sciences, Amrita Vishwa VidyapeethamKochiIndia

Personalised recommendations